Objective: To perform a systematic review and meta-analysis of studies reporting recurrent intracranial hemorrhage (ICH) and ischemic stroke (IS) in ICH survivors with atrial fibrillation (AF) during long-term follow-up.
Antithrombotic stroke prevention in patients with previous intracranial hemorrhage (ICH) and atrial fibrillation (AF) is challenging because ICH related to oral anticoagulant (OAC-ICH) is the most lethal complication of long-term anticoagulation and OACs are contraindicated after ICH. 1 In this setting, clinicians have to weigh the risk of thromboembolism against the risk of another ICH. Thromboembolic risk in patients with AF can be estimated with the CHA 2 DS 2 VASc score. 2 In contrast, there is only limited evidence on factors influencing the risk of recurrent ICH with and without anticoagulation, 3, 4 and clinical scores provide only modest help. 2, 5 No randomized controlled trial has studied the efficacy and safety of anticoagulation in patients with AF and ICH yet. The paucity of high-grade evidence is reflected in clinical guidelines, which refrain from making strong or even any recommendations for stroke prevention in patients with ICH and AF. 6, 7 The latest systematic review of the use of ATM after intracerebral hemorrhage focused on the risks of recurrent bleeding and thromboembolic events. 3 However, AF was not the only indication for ATM, and only intracerebral hemorrhage was considered. In the meantime, several large cohort studies have been published that explored antithrombotic therapy resumption after ICH.
We performed a systematic review and metaanalysis of studies reporting ischemic stroke (IS) and recurrent ICH in survivors of ICH with AF.
METHODS We performed a systematic review consistent with Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines (figure 1) following a prespecified protocol. 8 Our search strategy and data extraction are described in the e-supplement and table e-1 at Neurology.org.
Exposure and outcome measures. To calculate treatment exposure, the beginning of the observation period was set at 6 weeks after the index ICH. This 6-week landmark approach has been used in a large Danish nationwide registry 9 and may reduce selection bias derived from a nonrandomized allocation because very ill patients or patients at high risk for ICH recurrence could be considered unsuitable for OAC early after ICH. Data were requested and obtained from the corresponding authors of the studies because originally published data were not consistent with our 6-week quarantine period. Because treatment exposure was considered a time-dependent variable, a patient could contribute person-time to each of the groups at different times. This approach allowed us to calculate incidence rates and rate ratios (RRs).
For the purpose of our meta-analysis, we considered 3 different types of ATM exposure: vitamin K antagonists (VKAs), antiplatelet agents (APAs), or no antithrombotic medication (no-ATM). We also combined the APA and the no-ATM group into a no-VKA group. We assessed 2 primary endpoints: IS occurring between 6 weeks and 1 year of follow-up and ICH occurring between 6 weeks and 1 year of follow-up. For each endpoint, data on the number of events and the respective person-time of follow-up in each of the treatment groups were extracted. All investigators were asked to fill out prespecified tables with aggregate data based on individual data at study level.
Unadjusted incidence rates were calculated for each group and endpoint, as well as the respective incidence RRs for each pair of treatments. Only the first event during the follow-up contributed to the risk estimate. We conducted meta-analyses for the following pairs: (1) VKA vs no-VKA (i.e., APA and no-ATM combined), (2) VKA vs APA, (3) VKA vs no-ATM, and (4) APA vs no-ATM.
Finally, we calculated crude pooled event rates with associated 95% confidence intervals (CIs) for IS and ICH by pooling the total number of events (IS and ICH recurrences, respectively) and the respective cumulative follow-up, expressed in persontime, across all studies.
Risk of bias assessment. The quality of the studies was assessed according to the Cochrane handbook. 10 We used funnel plots for illustration of asymmetry and Egger regression test to get hints for publication bias. For the funnel plot, we plotted the standard error of the natural logarithm of the RR against the RR. A value of p , 0.1 was considered significant for publication bias.
Statistical analysis. The relative incidence rates of ICH and IS among the different groups in included studies were expressed as RR. The inverse variance method was used to conduct the metaanalysis, and pooled effects are presented as RR with 95% CI. Expecting considerable heterogeneity among studies because there was wide variation in study populations and study designs, we used random-effects models for the meta-analysis. 11 The I 2 statistic was calculated to quantify heterogeneity among included studies as low (,30%), moderate (30%-50%), or high (.50%). Single-variable meta-regression was used to explore whether mean age, sex, timing of ATM exposure, and type of hemorrhage (all ICH vs intracerebral hemorrhage only) were potential sources of significant heterogeneity. The lnRR weighted by inverse variance for each study was considered the dependent variable. Small study effects including publication bias were assessed with the Egger test and funnel plots.
All meta-analyses were performed with the Cochrane Review Manager 5.3 software (RevMan5.3). The Egger test and metaregression analyses were conducted with Comprehensive MetaAnalysis 3.0. Statistical significance levels were set at 0.05.
RESULTS
Seventeen articles, 14 full manuscripts and 3 conference abstracts, 12 ,e1,e2 of 3,455 originally identified citations met our inclusion criteria. Among included studies, 6 were prospective observational 13,e1,e3-e6 and 11 were retrospective studies. 9,12,14-17,e2,e7-e10 The index event was intracerebral hemorrhage in 11 studies 9,12-15,17,e2,e6-e8 and ICH in 6 studies. 16,e1,e3-e5,e10 Regarding the underlying cause, 11 studies addressed ICH related to ATM, 9,14-17,e1,e3,e6,e7,e9,e11 and 6 studies addressed a mixture of spontaneous and posttraumatic ICH. 12,13,e3,e5,e6,e9 Of all index ICH events, 97% occurred in anticoagulated patients; 3% were VKA naive. The inclusion criteria and the type of ATM used after the index event for each study are presented in table e-2.
Ten studies were excluded from the meta-analysis because of missing data or the absence of a comparison group. Seven studies were deemed suitable for inclusion in the meta-analysis.
9,12-17 A total of 2,452 patients (mean age 76 years, 41% female) were eligible. Characteristics of included studies are presented in table 1.
Pooled annual event rates for ICH recurrence and IS by antithrombotic strategy followed after the index ICH are presented in table 2.
Publication bias and quality assessment. The funnel plots showed asymmetry, suggesting possible publication bias (figures e-1 and e-2). No small study effects were detected by Egger test for either IS or ICH recurrence in all comparisons. All studies had possible selection bias. Overall, 71% of studies reported consecutive recruitment. Blinding of outcome assessment was performed in only one study. Attrition bias was found in 29% of studies. No funding bias was found in any of the included studies. Risk of reporting bias was low in all studies because data were provided directly by the corresponding authors. Other potential risks of bias are presented in table e-3.
VKAs vs no-VKAs. A total of 6 studies compared the rates of IS and ICH between patients who started a VKA and patients who did not start a VKA (no-VKA). The pooled RR of IS was significantly lower for VKA vs no-VKA patients (RR 5 0.46, 95% CI 0.29 to 0.72, p 5 0.0008, I
2 5 0%) ( figure 2A ). The rate of recurrent ICH was not significantly increased in VKA-treated compared to no-VKA patients (pooled RR 5 1.23, 95% CI 0.80 to 1.87, p 5 0.53, I
2 5 0%) (figure 3A).
VKAs vs APAs. Five studies provided data for comparison of VKAs and APAs. The pooled data showed a significant decrease in the rate of IS in patients treated with VKA vs APA (pooled RR 5 0.45, 95% CI 0.27 to 0.74, p 5 0.002, I 2 5 0%) (figure 2B). Again, the rate of ICH recurrence was not significantly higher AF is present in a substantial proportion of ICH survivors, with a prevalence of 12% to 14% in national registries and 30% in tertiary stroke centers. 18, 19 There is limited evidence on whether ATM should be started or withheld in this context. 20 ICH is the most feared complication of antithrombotic therapy, and the risk of ICH is higher in ICH survivors (3%-5% per year) 21 ,e5,e6,e9 compared to patients without previous ICH (0.3%-2.5% per year). [22] [23] [24] The paucity of evidence for efficacy and safety results in variation in restarting antithrombotic drugs in ICH survivors ranging from 11% to 45% across different health systems. 25 For example, although patients of Asian ethnicity have a higher risk of ICH than white patients, a nationwide survey in Japan reported that the majority of physicians support the resumption of OACs after ICH. 26 Our meta-analysis shows that prescribing VKA after VKA-associated ICH is associated with a reduction of IS by 45% to 47% compared to APA or no-ATM therapy. This effect size is similar to that in patients with AF without previous ICH. 27 Our results are supported by additional studies suggesting that ICH survivors with AF who do not start OAC treatment are at high risk of IS and mortality, both of which are significantly reduced by VKA. Pooled RR meta-analyses for IS that occurred between 6 weeks and 1 year of follow-up after exposure to different treatment strategies Pooled RR meta-analyses for ICH recurrence that occurred between 6 weeks and 1 year of follow-up after exposure to different treatment strategies Reinitiation of warfarin in Taiwanese ICH survivors with AF was beneficial. One study modeling risks and benefits calculated a net benefit of VKA for Asian patients with ICH with a CHA 2 DS 2 -VASc score $6, but this threshold was likely to be lower with direct OACs (DOACs). 28 In our analysis, which included mainly white patients with ICH, the median CHADS 2 score was 2, suggesting that starting OAC after ICH may be beneficial with only moderate thromboembolic risk.
9,15
We found no significantly increased risk for recurrent ICH with VKA, although the point estimate for the pooled RR was 23% to 32% higher compared to no-VKA and no-ATM. Previous research showed that ICH survivors carry a significant risk of recurrent ICH, e5,e7,e8 whereas studies found no increased risk of ICH recurrence e10 when they were treated with anticoagulants after the index event. Only early resumption of VKAs after warfarin-associated ICH increased the risk of recurrent ICH. 16 A recent Swedish nationwide cohort study suggests that anticoagulant treatment may be initiated 7 to 8 weeks after ICH in intracerebral hemorrhage survivors with AF to balance benefit from treatment against the risk of rebleeding. 29 In our meta-regression analysis, the timing of resumption failed to explain the lack of a significant difference for recurrent ICH between anticoagulated and nonanticoagulated patients, but early recurrent bleeding events were not captured in our study design.
OAC has a net clinical benefit in patients with AF without ICH. 30 Considering the significant decrease in the rate of IS with anticoagulants, a treatment option that provides a better safety profile than VKA may provide a net clinical benefit also to patients with ICH. DOACs have a favorable riskbenefit profile compared to VKA, resulting in a reduction in stroke and mortality. 31 In particular, DOACs are uniformly associated with a 50% reduced risk of ICH compared to VKA. 32 Limited information from a recent study based on national Danish registries supports this assumption. 33 Moreover, apixaban significantly reduced the risk of stroke and systemic embolism compared to aspirin without increasing the risk of ICH in A Phase III Study of Apixaban in Patients With Atrial Fibrillation (AVERROES). 34 Therefore, DOACs could be a better alternative for patients with ICH and AF. The ongoing Apixaban Versus Antiplatelet Drugs or no Antithrombotic Drugs After Anticoagulation-Associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation (APACHE-AF) pilot study (ClinicalTrials.gov NCT02565693) addresses stroke prevention with DOACs in ICH survivors with AF. Nonpharmacologic prevention strategies, including left atrial appendage occlusion, could be an alternative, but the evidence for this intervention in ICH survivors with AF is limited. 1, 35, 36 In addition to relative risks, decision making for a specific antithrombotic therapy has to take the absolute risks for ischemic and hemorrhagic events into account. A previous meta-analysis reported an annual risk of recurrent intracerebral hemorrhage of 1.3% to 7.4%, 4 whereas a prospective cohort study of patients with AF on VKA after ICH reported an ICH recurrence rate of 1.85 per person-year and no IS. e5 In our study, VKA users had a 0.4% to 0.9% higher pooled annual rate of ICH recurrence compared to the other treatment groups. On the contrary, the pooled annual event rate for IS was much lower in patients on VKA (3.2 per 100 patient-years) compared to the other treatment groups (APA: 9.5 per 100 patient-years, no-ATM: 6.1 per 100 patient-years). Although these data suggest a reduction of combined ischemic and hemorrhagic stroke event rates by VKA, they do not account for the different mortality and morbidity resulting from these different types of stroke.
Current American Heart Association guidelines recommend that APA monotherapy after any ICH might be considered and can be a reasonable alternative in patients with lobar hemorrhage, in whom OAC should be avoided. 6 The findings of the present meta-analysis do not support the use of APA for IS prevention because no effect on prevention of thromboembolic events was observed in patients with AF and ICH. Although older research found a smaller bleeding risk on APAs compared to VKAs, 37 the rate of ICH on aspirin was similar to that of well-managed VKAs 38 or DOACs. 34 However, the risk-benefit ratio of APA in ICH survivors with AF was unclear. The current analysis suggests that APAs do not increase the risk of ICH recurrence compared to VKAs or no-ATM.
Our systematic review and meta-analysis was based on a comprehensive search strategy that aimed to provide pooled estimates for IS and ICH recurrence in ICH survivors with AF after different prevention strategies. Thus, we can anticipate a low rate of underdetection. An important limitation of this large meta-analysis is the limited data quality of the mostly retrospective studies. For example, 3 studies relied on cohorts of patients derived from large national registries that use ICD-10 codes for medical diagnosis and Anatomical Therapeutic Chemical classification system codes to identify ATM. Because some deaths may be due to undiagnosed stroke and some minor strokes may have remained undetected, the risk of IS may be underreported. Using a 6-week landmark approach, we did not take into account bleeding complications related to the index ICH that may have been misclassified as ICH recurrences. Likewise, it is uncertain how many of the early recurrences were truly new events or just an extension of the initial bleeding site. 9 The included studies are highly prone to selection bias and confounding by indication because treating physicians may have avoided the use of VKAs in patients perceived to be at higher risk of recurrence. Hence, unmeasured selection bias is likely in that we were unable to calculate adjusted incidence RRs because individual patient data were not available in all studies. We summarized aggregated treatment group differences (baseline characteristics and comorbidities) (table e-5) for each study that may facilitate the interpretation of the results (table e-6). As previously shown, baseline adjustment in the setting of time-dependent exposure of treatment regimens only marginally affects outcomes associated with treatment. 9 This may indicate that other reasons (besides the measure and included variables) have affected the decision of resuming OAC treatment. This highlights the importance of meticulous interpretation of the associations because indication bias was likely present in all of the included studies. Another limitation is that we did not have information on either the time in therapeutic range for patients taking VKAs or the quality of blood pressure control. 39 We also did not have data on dropout and rates and directions of switch between different antithrombotic treatment strategies. The number of studies included in the meta-analysis was small; therefore, metaregression and publication bias assessments may have been underpowered and should be interpreted with caution. Our study focused on IS and ICH as the main outcome events. This approach may not provide the full picture of outcome events and other factors affecting the net clinical benefit. The 2 largest included studies showed a significant decrease of mortality in patients treated with VKAs. 9, 15 Because we censored patients after either IS or ICH, we did not capture potential multiple outcome events in individual patients, although ICH and IS are competing risk. Another limitation is that further subgroup analyses in terms of risk factors for ICH recurrence such as lobar vs deep hemorrhage topography, leukoaraiosis, and cerebral microbleed burden were not feasible because this information was missing in several studies. In addition, comorbidities apart from AF (e.g., coronary artery disease) indicating the use of antiplatelets were not addressed.
This meta-analysis of antithrombotic treatment in VKA-associated ICH survivors with AF suggests that anticoagulation with VKA is associated with a lower rate of IS compared to other or no antithrombotics without causing a major increase of the risk of ICH recurrence, whereas antiplatelets fail to prevent IS. Because of the limitations of observational studies, a randomized controlled trial of antithrombotic therapy, preferably with DOACs used as the anticoagulants, is needed to better guide decision making for antithrombotic therapy in patients with ICH and AF. 
